[
  {
    "ts": null,
    "headline": "Voya Corporate Leaders Trust Fund B Q1 2025 Commentary",
    "summary": "For the quarter, the Voya Corporates Leaders Trust Fund Series B outperformed its benchmark, the S&P 500 Index on a net asset value basis. Read more here.",
    "url": "https://finnhub.io/api/news?id=b6724170d78e966df6c9fa15888cdc632d010d8064f54dfef34e23537a3cab59",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748877900,
      "headline": "Voya Corporate Leaders Trust Fund B Q1 2025 Commentary",
      "id": 134957381,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2100234553/image_2100234553.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "For the quarter, the Voya Corporates Leaders Trust Fund Series B outperformed its benchmark, the S&P 500 Index on a net asset value basis. Read more here.",
      "url": "https://finnhub.io/api/news?id=b6724170d78e966df6c9fa15888cdc632d010d8064f54dfef34e23537a3cab59"
    }
  },
  {
    "ts": null,
    "headline": "Put Cash To Work: 2 Magnificent Dividends I'm Betting On",
    "summary": "Discover why RTX & AbbVie are top picks for growth & income.",
    "url": "https://finnhub.io/api/news?id=055adbcc07b3c97a6108e18da5df5139ba8c3f57b9c90f63dc0ab0c36819f5d2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748858400,
      "headline": "Put Cash To Work: 2 Magnificent Dividends I'm Betting On",
      "id": 134939270,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover why RTX & AbbVie are top picks for growth & income.",
      "url": "https://finnhub.io/api/news?id=055adbcc07b3c97a6108e18da5df5139ba8c3f57b9c90f63dc0ab0c36819f5d2"
    }
  },
  {
    "ts": null,
    "headline": "Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster.",
    "summary": "Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster.",
    "url": "https://finnhub.io/api/news?id=d997d158d45067defa40db36468fb001cc19cdd75b14f0315b79cb7ee1a10b7a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748850240,
      "headline": "Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster.",
      "id": 134940019,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster.",
      "url": "https://finnhub.io/api/news?id=d997d158d45067defa40db36468fb001cc19cdd75b14f0315b79cb7ee1a10b7a"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Income Update: Q1 2025",
    "summary": "Dividend Income Update: Q1 2025",
    "url": "https://finnhub.io/api/news?id=1bc48b021ccc0e439220f7bfc982ca2890ecaa20fefd222526528d0e2534448e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748843880,
      "headline": "Dividend Income Update: Q1 2025",
      "id": 134935601,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=1bc48b021ccc0e439220f7bfc982ca2890ecaa20fefd222526528d0e2534448e"
    }
  }
]